December 2002
Volume 43, Issue 13
ARVO Annual Meeting Abstract  |   December 2002
Electroretinogram Effects of Sustained Transscleral Drug Delivery of Carboplatin From Fibrin Sealant
Author Affiliations & Notes
  • JA Gilbert
    Ophthalmology Emory University Atlanta GA
  • C Hejny
    Ophthalmology Emory University Atlanta GA
  • MT Pardue
    Atlanta VA Hospital Atlanta GA
  • T Barnett
    Atlanta VA Hospital Atlanta GA
  • MJ Phillips
    Atlanta VA Hospital Atlanta GA
  • TM Aaberg
    Associated Retinal Consultants Grand Rapids and Royal Oak MI
  • DH Geroski
    Ophthalmology Emory University Atlanta GA
  • HF Edelhauser
    Ophthalmology Emory University Atlanta GA
  • Footnotes
    Commercial Relationships   J.A. Gilbert, None; C. Hejny, None; M.T. Pardue, None; T. Barnett, None; M.J. Phillips, None; T.M. Aaberg, None; D.H. Geroski, None; H.F. Edelhauser, None. Grant Identification: Support: NEI Core Grant P30-EY06360
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2587. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JA Gilbert, C Hejny, MT Pardue, T Barnett, MJ Phillips, TM Aaberg, DH Geroski, HF Edelhauser; Electroretinogram Effects of Sustained Transscleral Drug Delivery of Carboplatin From Fibrin Sealant . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2587.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To evaluate subconjunctivally injected carboplatin in fibrin sealant as a possible treatment for retinoblastoma, ERGs were performed on rabbits to test for retinal toxicity. Methods: One group of rabbits received a unilateral subconjunctival injection of carboplatin (Paraplatin®) impregnated in fibrin sealant (Hemaseel APR®), which had a final concentration of 20.4 ± 7.3 mg/mL. Another group of rabbits received 11.2 ± 0.8 mg/mL of carboplatin in balanced salt solution (BSS), the currently used vehicle. Two additional control groups of rabbits were similarly injected with fibrin sealant and BSS without carboplatin. Baseline ERGs were performed on all rabbits prior to injection and at 2 days, 1, 2, and 3 weeks after injection. During each testing session, the animals were dark adapted for two hours, anesthetized, and pupils were dilated with 1% tropicamide and 2.5% phenylephrine HCl. The ERG was recorded with a Jet contact lens electrode with a 6mm Grass cup reference electrode placed in the mouth and a 1 cm needle ground electrode placed subcutaneously in the trunk. Signals were amplified (.01 to 1,000 Hz), averaged and stored using a Diagnosys Espion System. Flash stimuli were presented in order of increasing intensity to both dark-adapted eyes using a bifurcated fiber optic cable with a Diagnosys hand-held ganzfeld. Following 10 minutes of light adaptation, a light-adapted intensity series was presented to isolate cone function. Atomic absorption spectrophotometry was used to confirm the concentration of carboplatin in each injection. Results: Both dark and light-adapted ERG amplitudes and implicit times showed no significant changes from control eyes at any time after treatment with carboplatin in either vehicle or in the vehicles alone. Conclusion: At the current concentrations, the use of locally administered carboplatin in fibrin sealant does not adversely affect retinal function and remains a feasible approach in delivering carboplatin in a time-released fashion for the treatment of retinoblastoma. Support: NEI Core Grant P30-EY06360, Knights Templar Educational Foundation, Foundation Fighting Blindness, RPB, Inc., and Department of Veterans Affairs.

Keywords: 390 drug toxicity/drug effects • 396 electroretinography: non-clinical • 569 retinoblastoma 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.